Yalta, KenanYetkin, ErtanYalta, Tuelin2024-05-192024-05-1920232146-31232146-3131https://doi.org10.4274/balkanmedj.galenos.2023.2023-2-14https://hdl.handle.net/20.500.12713/5935In cardiooncology practice, early cardiotoxicity refers to an emerging subclinical myocardial dysfunction/injury in response to certain chemotherapeutic regimens. This condition can progress to overt cardiotoxicity in time and hence warrants proper and timely diagnostic and preventive strategies. Current diagnostic strategies for early cardiotoxicity are largely based on conventional biomarkers and certain echocardiographic indices. However, a significant gap still exists in this setting, warranting further strategies to improve diagnosis and overall prognosis in cancer survivors. Copeptin (surrogate marker of the arginine vasopressine axis) might serve as a promising adjunctive guide for the timely detection, risk stratification, and management of early cardiotoxicity on top of conventional strategies largely due to its multifaceted pathophysiological implications in the clinical setting. This work aims to focus on serum copeptin as a marker of early cardiotoxicity and its general clinical implications in patients with cancer.eninfo:eu-repo/semantics/openAccessArginine-Vasopressin IncreasesLeft-Ventricular DysfunctionHigh-Dose ChemotherapyLong-Term SurvivalInduced CardiotoxicityPrognostic ValueStable PeptideTakotsubo CardiomyopathyCancer-PatientsTroponin-IReview Article402829236883738WOS:0009525220000032-s2.0-85149533385N/A10.4274/balkanmedj.galenos.2023.2023-2-14Q3